Long-term efficacy and safety of tofacitinib in patients with ulcerative colitis: 3-year results from a real-world study.

ABSTRACT:

Background/aims

The efficacy and safety of tofacitinib for the treatment of refractory ulcerative colitis (UC) has been demonstrated in clinical trials. Although, a series of reports with real-world evidence of its short-term efficacy and safety profiles have already been published, reports of long-term real-world data have been limited. We aimed to show our 3-year evidence on the clinical use of tofacitinib for the treatment of UC, focusing on its efficacy and safety profiles.

Methods

A retrospective observational study was conducted on patients who started tofacitinib for active refractory UC at our hospital. The primary outcome was the retention rate until 156 weeks after initiating tofacitinib. The secondary outcomes were short-term efficacy at 4, 8, and 12 weeks; long-t

SUBMITTER: Shimizu H 

PROVIDER: S-EPMC11309816 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature